Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 20/20 | 0.84 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.81 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.73 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5562678 | 0.92 | SLC6A9 (1.00) | SLC6A9OPRM1KCNH2OPRL1 | |
| SCHEMBL5557836 | 0.90 | SLC6A9 (1.00) | SLC6A9OPRM1KCNH2OPRL1 | |
| SCHEMBL5563588 | 0.90 | SLC6A9 (0.84) | SLC6A9OPRM1KCNH2OPRL1 | |
| SCHEMBL5557128 | 0.90 | SLC6A9 (0.84) | SLC6A9OPRM1KCNH2OPRL1 | |
| SCHEMBL5564999 | 0.89 | SLC6A9 (1.00) | SLC6A9OPRM1KCNH2OPRL1 | |
| SCHEMBL5562071 | 0.89 | SLC6A9 (1.00) | SLC6A9OPRM1KCNH2OPRL1 | |
| SCHEMBL5562088 | 0.86 | SLC6A9 (0.89) | SLC6A9OPRM1KCNH2OPRL1 | |
| SCHEMBL5557340 | 0.85 | SLC6A9 (1.00) | SLC6A9OPRM1KCNH2OPRL1 | |
| SCHEMBL5557332 | 0.85 | SLC6A9 (1.00) | SLC6A9OPRM1KCNH2OPRL1 | |
| SCHEMBL5556587 | 0.85 | SLC6A9 (1.00) | SLC6A9OPRM1KCNH2OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7265126-B2 | Diaza-spiropiperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-09-04 | — | — | US | claimed |
| EP-1716147-B1 | DIAZA-SPIROPIPERIDINE DERIVATIVES AS INHIBITORS OF GLYCINE TRANSPORTER 1 AND GLYCINE TRANSPORTER 2 | HOFFMANN LA ROCHE (CH) | 2007-11-14 | — | — | EP | disclosed |
| US-7265126-B2 | Diaza-spiropiperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-20050154000-A1 | Diaza-spiropiperidine derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154000-A1 | Diaza-spiropiperidine derivatives | AVPR1A, AVPR1B, QDPR | SLC6A9 1752/4885OPRM1 1974/4885KCNH2 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.